All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This study is an open-labeled, multicenter, single arm, observational post-marketing surveillance study under routine clinical practice with no mandated treatments, visits or assessments.
Retinopathy of Prematurity
Jun 22, 2022
Jan 12, 2025
10 Years and older (Child)
There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
Premature infants with retinopathy of prematurity (ROP)
Patients (infants) prescribed with Lucentis® injection according to the product approval information in the Republic of Korea
In the case that the legal guardian of the patient (infant) provided a written consent to participate in this study
In the case that the legal guardian of the patient (infant) does not want participation in this study
In the case that it falls under any of the contraindications listed in local prescribing information of Lucentis® injection
Patients with hypersensitivity to the active substance or to any of the excipients
Patients with an active or suspected ocular or periocular infection.
Patients with active intraocular inflammation